Urogenit Tract Infect.  2018 Apr;13(1):1-6. 10.14777/uti.2018.13.1.1.

The Effect of α-Blockers Monotherapy vs. Combination Antibiotic Therapy on Symptom Alleviation in Patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome

• Kim KS
• Moon HS

• KMID: 2410716
• DOI: http://doi.org/10.14777/uti.2018.13.1.1

Abstract

Prostatitis is a pathologic state of prostate inflammation accompanied by lower urinary tract symptoms and pelvic pain, reducing the quality of life in males of all ages. There is currently no established treatment modality for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). In this review, alpha-blocker monotherapy was compared with combination antibiotic therapies. Alpha-blockers are the most commonly used medications to treat CPPS, administered to over 40% of CPPS patients. The use of antibiotics in CP/CPPS is an alternative treatment option. There are no studies showing the efficacy of antibiotics in CP/CPPS patients. However, antibiotics are commonly prescribed to patients with CP/CPPS, often leading to patient improvement. A combined regimen of alpha-blocker, antibiotic, and anti-inflammatory therapy showed improvement in patient symptoms; however, the results were similar to monotherapy with alpha-blockers. When alpha-blocker monotherapy was compared with three multidrug therapies via randomized controlled trials, monotherapy was shown to be more effective than multidrug treatment. There is no definite treatment for CP/CPPS because it is caused by various factors, and symptoms are different for each patient. CP/CPPS patient care should be managed in a manner that identifies and treats all symptoms simultaneously and appropriately. Recently, urinary, psychosocial, organ-specific, infection, neurologic/systemic, and tenderness (UPOINT) was introduced in order to better treat patients. However, UPOINT has not been extensively studied in clinical trials, and the mechanical principles of UPOINT have yet to be elucidated. Alpha-blocker monotherapy and antibiotic combination therapy showed considerable improvement in CP/CPPS patients (by National Institutes of Health Chronic Prostatitis Symptom Index scores).

Keyword

Prostatitis; Anti-bacterial agents; Monotherapy

MeSH Terms

Anti-Bacterial Agents
Humans
Inflammation
Lower Urinary Tract Symptoms
Male
National Institutes of Health (U.S.)
Patient Care
Pelvic Pain*
Prostate
Prostatitis
Quality of Life
Anti-Bacterial Agents

Reference

1. Yoon BI, Kim S, Han DS, Ha US, Lee SJ, Kim HW, et al. Acute bacterial prostatitis: how to prevent and manage chronic infection? J Infect Chemother. 2012; 18:444–450.

2. de la Rosette JJ, Hubregtse MR, Meuleman EJ, Stolk-Engelaar MV, Debruyne FM. Diagnosis and treatment of 409 patients with prostatitis syndromes. Urology. 1993; 41:301–307.

3. Schaeffer AJ, Darras FS. The efficacy of norfloxacin in the treatment of chronic bacterial prostatitis refractory to trimethoprim-sulfamethoxazole and/or carbenicillin. J Urol. 1990; 144:690–693.

4. Pust RA, Ackenheil-Koppe HR, Gilbert P, Weidner W. Clinical efficacy of ofloxacin (tarivid) in patients with chronic bacterial prostatitis: preliminary results. J Chemother. 1989; 1:4 Suppl. 869–871.

5. Nickel JC. Treatment of chronic prostatitis/chronic pelvic pain syndrome. Int J Antimicrob Agents. 2008; 31:Suppl 1. S112–S116.

6. Schaeffer A, Anderson R, Krieger J. The assessment and management of male pelvic pain syndrome, including prostatitis. In : McConnell J, Abrams P, Denis L, editors. Male lower urinary tract dysfunction, evaluation and management. 6th International Consultation on New Developments in Prostate Cancer and Prostate Disease. Paris: Health Publications;2006. p. 341–385.

7. Zhu QF, Xie H, Weng ZL, Yang YR, Chen BC. Detection of bacterial signal of 16S rRNA gene in prostate tissues obtained by perineal approach from patient with chronic pelvic pain syndrome. Zhonghua Yi Xue Za Zhi. 2009; 89:823–825.

8. Bergner M, Bobbitt RA, Pollard WE, Martin DP, Gilson BS. The sickness impact profile: validation of a health status measure. Med Care. 1976; 14:57–67.

9. Schneider H, Wilbrandt K, Ludwig M, Beutel M, Weidner W. Prostate-related pain in patients with chronic prostatitis/chronic pelvic pain syndrome. BJU Int. 2005; 95:238–243.

10. Ku JH, Kim SW, Paick JS. Epidemiologic risk factors for chronic prostatitis. Int J Androl. 2005; 28:317–327.

11. Nickel JC. Prostatitis: lessons from the 20th century. BJU Int. 2000; 85:179–185.

12. Schaeffer AJ, Landis JR, Knauss JS, Propert KJ, Alexander RB, Litwin MS, et al. Demographic and clinical characteristics of men with chronic prostatitis: the national institutes of health chronic prostatitis cohort study. J Urol. 2002; 168:593–598.

13. Trevisani M, Campi B, Gatti R, André E, Materazzi S, Nicoletti P, et al. The influence of alpha1-adrenoreceptors on neuropeptide release from primary sensory neurons of the lower urinary tract. Eur Urol. 2007; 52:901–908.

14. Schwinn DA, Roehrborn CG. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol. 2008; 15:193–199.

15. Mehik A, Alas P, Nickel JC, Sarpola A, Helström PJ. Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study. Urology. 2003; 62:425–429.

16. Nickel JC, Krieger JN, McNaughton-Collins M, Anderson RU, Pontari M, Shoskes DA, et al. Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. N Engl J Med. 2008; 359:2663–2673.

17. Nickel JC, O'Leary MP, Lepor H, Caramelli KE, Thomas H, Hill LA, et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double-blind, placebo controlled study. J Urol. 2011; 186:125–131.

18. Nickel JC, Narayan P, McKay J, Doyle C. Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. J Urol. 2004; 171:1594–1597.

19. Chen Y, Wu X, Liu J, Tang W, Zhao T, Zhang J. Effects of a 6-month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial. World J Urol. 2011; 29:381–385.

20. Tuğcu V, Taşçi AI, Fazlioğlu A, Gürbüz G, Ozbek E, Sahin S, et al. A placebo-controlled comparison of the efficiency of triple- and monotherapy in category III B chronic pelvic pain syndrome (CPPS). Eur Urol. 2007; 51:1113–1117.

21. Cheah PY, Liong ML, Yuen KH, Teh CL, Khor T, Yang JR, et al. Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. Urology. 2004; 64:881–886.

22. Cheah PY, Liong ML, Yuen KH, Teh CL, Khor T, Yang JR, et al. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. J Urol. 2003; 169:592–596.

23. Shoskes DA. Use of antibiotics in chronic prostatitis syndromes. Can J Urol. 2001; 8:Suppl 1. 24–28.

24. Schaeffer AJ. Clinical practice. Chronic prostatitis and the chronic pelvic pain syndrome. N Engl J Med. 2006; 355:1690–1698.

25. Nickel JC, Shoskes DA, Wagenlehner FM. Management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): the studies, the evidence, and the impact. World J Urol. 2013; 31:747–753.

26. Nickel JC, Downey J, Clark J, Casey RW, Pommerville PJ, Barkin J, et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial. Urology. 2003; 62:614–617.

27. Zhou Z, Hong L, Shen X, Rao X, Jin X, Lu G, et al. Detection of nanobacteria infection in type III prostatitis. Urology. 2008; 71:1091–1095.

28. Engeler D, Baranowski AP, Elneil S, Hughes J, Messelink EJ, van Ophoven A, et al. Guidelines on chronic pelvic pain. European Association of Urology;2012.

29. Nickel JC, Downey J, Johnston B, Clark J. Canadian Prostatitis Research Group. Predictors of patient response to antibiotic therapy for the chronic prostatitis/chronic pelvic pain syndrome: a prospective multicenter clinical trial. J Urol. 2001; 165:1539–1544.

30. Ye ZQ, Lan RZ, Yang WM, Yao LF, Yu X. Tamsulosin treatment of chronic non-bacterial prostatitis. J Int Med Res. 2008; 36:244–252.

31. Alexander RB, Propert KJ, Schaeffer AJ, Landis JR, Nickel JC, O'Leary MP, et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial. Ann Intern Med. 2004; 141:581–589.

32. Jeong CW, Lim DJ, Son H, Lee SE, Jeong H. Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination. Urol Int. 2008; 80:157–161.

33. Kim TH, Lee KS, Kim JH, Jee JY, Seo YE, Choi DW, et al. Tamsulosin monotherapy versus combination therapy with antibiotics or anti-inflammatory agents in the treatment of chronic pelvic pain syndrome. Int Neurourol J. 2011; 15:92–96.

34. Shoskes DA, Nickel JC, Rackley RR, Pontari MA. Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes. Prostate Cancer Prostatic Dis. 2009; 12:177–183.